Skip to main content

Table 1 Characteristics of subjects

From: A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia

  Placebo group Tropisetron group P value
Sex (M/F) 10/10 9/11 NSa
Age 35.15 ± 8.54 34.96 ± 6.82 NSb
Subtype Disorganised 1 Disorganised 0 NSa
  Catatonia 1 Catatonia 0  
  Paranoid 13 Paranoid 11  
  Undifferentiated 2 Undifferentiated 3  
  Residual 3 Residual 6  
Duration of illness 9.79 ± 6.43 12 ± 8.67 NSb
Dose of risperidone 3.8 ± 1.58 4.03 ± 1.59 NSb
No. smoking 5 (25%) 6 (30%) NSa
Full IQ 87.00 ± 16.80 87.68 ± 18.86 NSb
PANSS score Positive: 11.8 ± 3.12 Positive: 11.85 ± 3.22 NSb
  Negative: 18.45 ± 6.66 Negative: 18.95 ± 5.23  
  General: 34.3 ± 7.53 General: 33.75 ± 8.69  
  Total: 64.55 ± 15.17 Total: 64.55 ± 15.65  
QLS total score 77.05 ± 15.8 72.2 ± 13.95 NSb
Rate of completion 17 (85%) 16 (80%) NSa
Reason for dropout Physical illness: 1 Non-adherence: 2  
  Worsening of illness: 1 Unknown: 1  
  Adverse effects: 1 (extrapyramidal signs) Adverse effect: 1 (chest pain)  
  1. Data show the mean ± SD.
  2. aχ2 test; bStudent t test.
  3. NS = not significant; PANSS = Positive and Negative Syndrome Scale; QLS = Quality of Life Scale.